NCT00015821View on ClinicalTrials.gov

Thalidomide in Treating Patients With Myelofibrosis

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

May 31, 2000

Primary Completion Date

December 31, 2007

Conditions
Primary Myelofibrosis
Interventions
DRUG

thalidomide

Given PO

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

55905

North Central Cancer Treatment Group, Rochester

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00015821 - Thalidomide in Treating Patients With Myelofibrosis | Biotech Hunter | Biotech Hunter